Overview

Stem Cells in Myocardial Infarction

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this trial is to investigate the effect of treatment with granulocyte-colony stimulating factor (G-CSF) bone marrow stimulation on circulating stem cells' ability to develop new blood vessels in the myocardium after an acute myocardial infarction.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rigshospitalet, Denmark
Treatments:
Lenograstim
Sargramostim
Criteria
Inclusion Criteria:

- Patients between 20 and 70 years with STEMI were eligible if they had a successful PCI
within 12 hours after onset of symptoms.

- The target lesion had to be located in the proximal section of the left anterior
descending (LAD), left circumflex (LCX) or right coronary artery (RCA).

- Only patients with creatine kinase [CK]-MB >100 microgram/L or development of Q waves
in the electrocardiogram were included.

Exclusion Criteria:

- Ventricular arrhythmia after PCI requiring treatment

- Pregnancy

- Unprotected left main stem lesion

- History of prior myocardial infarction

- Diagnosed or suspected cancer

- New York Heart Association (NYHA) class 3-4

- Known severe claustrophobia

- Significant stenosis in another coronary vessel than the acutely treated vessel, that
might demand treatment with PCI or coronary artery bypass graft surgery (CABG) prior
to the last follow-up exam.